Morningstar's Josh Peters on considering yield and growth when looking for dividend-stock opportunities.
Valuations for pharmaceutical companies should rebound once investors look past today's patent expirations to tomorrow's new drugs, says Morningstar's Damien Conover.
Probably in the first quarter, we're going to see the first major round of dividend increases from the country's big banks that have returned to profitability, says Morningstar's Josh Peters.
Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.
Good day, and welcome to the First Quarter 2012 Earnings Release Conference Call. This call is being recorded.
©2012 Morningstar Advisor. All right reserved.